Clinical Trial Update: Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer. [Phase 1]

View source ↗

Summary

Phase I trial evaluating the combination of afatinib and trastuzumab in HER2-overexpressing cancers (breast and stomach), with the study completed and results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Stomach Cancer

Drugs mentioned

• Afatinib (afatinib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Breast Neoplasms, Stomach Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2017-11-06